US Pharm. 2012;37(4):1.
Abbott Park, IL—Abbott Laboratories has announced that its pharmaceutical division will be known as AbbVie by late 2012. It will be a separate, publicly traded company from its parent. Drugs include the top-selling Humira for arthritis, Lupron for prostate cancer, and Synagis for respiratory virus. Richard A. Gonzalez, currently executive vice president, Global Pharmaceuticals, has been named CEO of the new company. Abbott Laboratories will retain its name and focus on nutritional products, branded generics, and medical devices. AbbVie will be located at Abbott’s campus near Chicago and will account for approximately 45% of the company’s revenue.
To comment on this article, contact rdavidson@uspharmacist.com.
